ArticleStem cell reviews and reports2026
Directly Thawed Bone Marrow Mesenchymal Stromal Cells Retain Mechanism of Action and Support Bone Clinical Translation.
Article in Stem cell reviews and reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMesenchymal stromal cells (MSCs) are currently employed in numerous clinical protocols, and have been used to enhance the regeneration of bone tissue in case of osteonecrosis, long bone and maxillary bone defects. Traditionally, these protocols were designed using freshly harvested, cultured MSCs. However, several limitations arose due to logistical issues, revealing the need to modify the protocol to facilitate the clinical process. In this context, cryopreservation and the use of the MSCs immediately after thawing seem to be the easiest way to overcome most of these constraints.
methodsBone marrow MSCs (BMSCs) of three donors were compared immediately after harvesting or thawing. First, the kinetics of cell viability and the gene expression profile were assessed in vitro. Then, the role of the cells in supporting vasculogenesis and bone formation in vivo was assessed using molecular biology and histology.
resultsFirstly, we observed a reduction in cell viability immediately after thawing, but no difference after 2 h. Furthermore, the gene expression profile was equivalent for genes involved in osteoblastic differentiation, vasculogenesis, inflammatory cytokines and proliferation. These in vitro results were confirmed by in vivo assays, which showed that cryopreservation did not affect their inflammatory response or vasculogenesis potential. Additionally, analysis of cell survival kinetics and bone formation assays revealed that cryo- and fresh-BMSCs exhibit equivalent potential to induce new bone formation and participate directly in bone formation, as evidenced by the expression of human osteoblastic genes.
conclusionOur study demonstrated that cryo-BMSCs possess the same properties as fresh BMSCs. Therefore, using cryo-BMSCs appears to be the optimal approach for future bone tissue engineering protocols and will facilitate the establishment of a BMSCs bank for future clinical trials.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.